# Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer

> **NCT00114816** · PHASE3 · COMPLETED · sponsor: **Finnish Breast Cancer Group** · enrollment: 1500 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00114816
- **Lead sponsor:** Finnish Breast Cancer Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** —
- **Final completion:** 2007-04
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2007-05-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00114816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00114816, "Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT00114816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*